Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Leukemia

• Publication date

  2017-01-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2017.35PMID 28111466
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma

  2017cited by this paper
• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

  2016cited by this paper
• Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

  2015cited by this paper
• Autologous transplantation and maintenance therapy in multiple myeloma.

  2014cited by this paper
• Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

  2014cited by this paper
• A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.

  2013cited by this paper
• Implications of continued response after autologous stem cell transplantation for multiple myeloma.

  2013cited by this paper
• Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

  2012cited by this paper
• The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

  2012cited by this paper
• Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

  2012cited by this paper
• Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

  2012cited by this paper
• Lenalidomide after stem-cell transplantation for multiple myeloma.

  2012cited by this paper
• Molecular Mechanisms of Pro-Survival and Differentiating Function of Bone Marrow-Derived Adipocytes On Acute Monoblastic Leukemia Cells.

  2012cited by this paper
• Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

  2012cited by this paper
• Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

  2012cited by this paper
• A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

  2010cited by this paper
• Hematopoietic stem cell transplantation for multiple myeloma beyond 2010.

  2010cited by this paper
• Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

  2009cited by this paper
• Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

  2008cited by this paper
• Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7

  2007cited by this paper
• Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

  2006cited by this paper
• High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

  2005cited by this paper
• Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.

  2002cited by this paper
• Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

  2001cited by this paper
• Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.

  2000cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

  1973cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• The Evolving Landscape of Anti-Clonal Therapy in Newly Diagnosed Systemic Light-Chain (AL) Amyloidosis: Evidence- and Time-Based Comparison with Multiple Myeloma.

  2026cites this paper
• Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

  2026cites this paper
• Integrating an updated high-risk multiple myeloma classification into clinical practice and clinical trial epidemiology.

  2026cites this paper
• Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs

  2025cites this paper
• Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study

  2025influential citation
• Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review

  2024cites this paper
• Historical Perspective of High-Dose Therapy Followed by Autologous Stem Cell Transplantation in Multiple Myeloma

  2024influential citation
• Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation

  2024cites this paper
• The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT

  2024cites this paper
• Meta-Analysis of Long-Term Effectiveness of Bortezomib in Managing Multiple Myeloma

  2024cites this paper
• The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis

  2024influential citation
• Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management.

  2024cites this paper
• High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience

  2024cites this paper
• Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation

  2023cites this paper
• LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA.

  2023cites this paper
• [Multiple Myeloma Treatment Guidelines by the Portuguese Group of Multiple Myeloma].

  2023cites this paper
• Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.

  2023cites this paper
• How I Treat Relapsed Multiple Myeloma.

  2022cites this paper
• Newly diagnosed multiple myeloma: making sense of the menu.

  2022cites this paper
• Multiple Myeloma

  2022cites this paper
• Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms

  2022cites this paper
• Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis

  2022cites this paper
• Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant

  2022cites this paper
• Maintenance Therapy With Bortezomib and Dexamethasone for Transplant-ineligible Patients With Multiple Myeloma.

  2021cites this paper
• Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum

  2021cites this paper
• Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation

  2021cites this paper
• Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline

  2021cites this paper
• Post-Transplant Maintenance Treatment Options in Multiple Myeloma

  2021cites this paper
• Efficacy of proteasome inhibitor‐based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta‐analysis

  2020cites this paper
• The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review.

  2020cites this paper
• Peripheral neuropathy in hematologic malignancies - Past, present and future.

  2020cites this paper
• Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

  2020cites this paper
• Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis

  2020cites this paper
• Developments in consolidation and maintenance strategies in post-remission multiple myeloma

  2020cites this paper
• Maintenance Strategies After Hematopoietic Cell Transplantation

  2020cites this paper
• Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

  2020influential citation
• Frühe Rekonstitution zirkulierender Antikörper-sezernierender Zellen nach haploidenter Stammzelltransplantation

  2020cites this paper
• Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study.

  2020cites this paper
• Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation

  2020cites this paper
• Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible

  2020cites this paper
• Emerging agents and regimens for multiple myeloma

  2020cites this paper
• Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching

  2020influential citation
• The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma

  2019cites this paper
• Moving Toward Continuous Therapy in Multiple Myeloma

  2019cites this paper
• Management of cardiovascular risk in patients with multiple myeloma

  2019cites this paper
• Risk adapted post-transplant maintenance in multiple myeloma

  2019cites this paper
• The role and value of maintenance therapy following autologous stem cell transplant in multiple myeloma

  2019cites this paper
• Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials

  2019cites this paper
• Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.

  2019cites this paper
• Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.

  2019cites this paper
• Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies

  2019cites this paper
• A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma

  2019cites this paper
• Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.

  2019cites this paper
• Maintenance and continuous therapy for multiple myeloma

  2018cites this paper
• The evolution of stem-cell transplantation in multiple myeloma

  2018cites this paper
• Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials

  2018influential citation
• Insights on Multiple Myeloma Treatment Strategies

  2018influential citation
• Magnetic Resonance Imaging of Bone Marrow and its Results as a Criterion for Administration of Maintenance Therapy After Auto-HSCT in Multiple Myeloma Patients

  2018cites this paper
• Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.

  2018cites this paper
• Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

  2018cites this paper
• Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side

  2018cites this paper
• Targeted therapy and maintenance in myeloma

  2017cites this paper
• From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

  2017cites this paper
• The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma

  2017cites this paper
• Fixed duration vs continuous therapy in multiple myeloma.

  2017cites this paper
• Management of multiple myeloma in the newly diagnosed patient.

  2017cites this paper